Markets | | | The screener enables traders to track the price movements of specific stocks and further monitor various signals and indicators. While the platform is not without its fair share of drawbacks, it is a useful resource for both new and experienced traders. Read the Full Story |
|
|
Stocks | | | Active value managers and value as a portfolio factor have underperformed the indexes since the global financial crisis. This lead to mass redemptions from top value managers like Greenlight and Pershing Square, and the proclamation of value’s death from financial pundits.
Investment strategi... Read the Full Story |
|
Markets | | | Trulieve is a vertically integrated cannabis producer, this means that they cultivate cannabis and also sell it in their own retail stores. The company calls this “seed-to-sale” integration. They’re primarily a server of the Florida medical marijuana market, with a sizable portion ... Read the Full Story |
|
|
Markets | | | Quantitative investing is infinitely easier to implement on an individual level than it’s trading counterpart. It simply comes down to identifying factors that outperform and setting appropriate position balancing, risk management, and rebalancing criteria.
Investing quantitatively protects u... Read the Full Story |
|
Markets | | |
If you’re like most investors, you’ve spent a lot of time thinking about your retirement, and with good reason. According to the U.S. Census Bureau, the median household income is approximately $62,000. The average household income is only about $11,000 higher.
This means that the ave... Read the Full Story |
|
From Our PartnersWith the next presidential cycle heating up and Trump leading the charge, major market shifts are already taking shape.
For investors who position early, the opportunities could be significant.
That’s why we’ve just released a brand-new report:
📈 “5 Best Stocks to Buy Under Trump’s Presidency.” | | | Get the full report here—and stay ahead of the curve. |
|
The Early Bird Stock Of The Day IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. | | View Today's Stock Pick |
|
